|

Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer

RECRUITINGSponsored by Minia University
Actively Recruiting
SponsorMinia University
Started2025-02-01
Est. completion2026-02-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06978322

Summary

This trial aimed to determine whether neoadjuvant chemoradiotherapy improves overall survival compared with upfront surgery, both followed by adjuvant chemotherapy in patients with resectable and borderline resectable pancreatic cancer.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Computed tomography (CT) with pancreatic protocol + vascular mapping
* Histopathologically proven malignant by CT-guided or endoscopic ultrasound (EUS)-guided biopsy Resectable pancreatic cancer means no contact of the tumor with the Superior mesenteric artery, Celiac axis \& Common hepatic artery, and contact of the tumor but ≤90° contact with the superior mesenteric vein \& portal vein.

Exclusion Criteria:

* Borderline resectable \& locally advanced pancreatic cancer
* Tumor at the tail of the pancreas.
* Metastatic pancreatic cancer
* Unfit patients for surgery.

Conditions5

CancerManagementNeoadjuvant ChemotherapyResectable Pancreatic CancerSurgery

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.